1 序文
2 調査範囲と方法論
2.1 調査の目的
2.2 ステークホルダー
2.3 データソース
2.3.1 一次情報源
2.3.2 二次情報源
2.4 市場推定
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法
3 エグゼクティブ・サマリー
4 はじめに
4.1 概要
4.2 主要産業動向
5 世界の医療用大麻市場
5.1 市場概要
5.2 市場パフォーマンス
5.3 COVID-19の影響
5.4 品種別市場構成
5.5 誘導体別市場構成比
5.6 用途別市場構成比
5.7 用途別市場構成比
5.8 投与経路別市場構成比
5.9 地域別市場構成比
5.10 市場予測
5.11 SWOT分析
5.11.1 概要
5.11.2 強み
5.11.3 弱点
5.11.4 機会
5.11.5 脅威
5.12 バリューチェーン分析
5.12.1 インプットサプライヤー
5.12.2 コレクター
5.12.3 メーカー
5.12.4 流通業者
5.12.5 輸出業者
5.12.6 小売業者
5.12.7 エンドユーザー
5.13 ポーターズファイブフォース分析
5.13.1 概要
5.13.2 買い手の交渉力
5.13.3 供給者の交渉力
5.13.4 競争の程度
5.13.5 新規参入の脅威
5.13.6 代替品の脅威
5.14 主な成功要因とリスク要因
6 品種別市場構成
6.1 インディカ種
6.1.1 市場動向
6.1.2 市場予測
6.2 サティバ
6.2.1 市場動向
6.2.2 市場予測
6.3 ハイブリッド
6.3.1 市場動向
6.3.2 市場予測
7 誘導体別市場構成
7.1 カンナビジオール（CBD）
7.1.1 市場動向
7.1.2 市場予測
7.2 テトラヒドロカンナビノール（THC）
7.2.1 市場動向
7.2.2 市場予測
7.3 その他
7.3.1 市場動向
7.3.2 市場予測
8 用途別市場
8.1 癌
8.1.1 市場動向
8.1.2 市場予測
8.2 関節炎
8.2.1 市場動向
8.2.2 市場予測
8.3 片頭痛
8.3.1 市場動向
8.3.2 市場予測
8.4 てんかん
8.4.1 市場動向
8.4.2 市場予測
8.5 その他
8.5.1 市場動向
8.5.2 市場予測
9 用途別市場
9.1 医薬品産業
9.1.1 市場動向
9.1.2 市場予測
9.2 研究開発センター
9.2.1 市場動向
9.2.2 市場予測
9.3 その他
9.3.1 市場動向
9.3.2 市場予測
10 投与経路別市場内訳
10.1 経口剤・カプセル
10.1.1 市場動向
10.1.2 市場予測
10.2 気化器
10.2.1 市場動向
10.2.2 市場予測
10.3 外用剤
10.3.1 市場動向
10.3.2 市場予測
10.4 その他
10.4.1 市場動向
10.4.2 市場予測
11 地域別市場内訳
11.1 北米
11.1.1 米国
11.1.1.1 市場動向
11.1.1.2 市場予測
11.1.2 カナダ
11.1.2.1 市場動向
11.1.2.2 市場予測
11.2 欧州
11.2.1 ドイツ
11.2.1.1 市場動向
11.2.1.2 市場予測
11.2.2 イタリア
11.2.2.1 市場動向
11.2.2.2 市場予測
11.2.3 フランス
11.2.3.1 市場動向
11.2.3.2 市場予測
11.2.4 オランダ
11.2.4.1 市場動向
11.2.4.2 市場予測
11.2.5 スペイン
11.2.5.1 市場動向
11.2.5.2 市場予測
11.3 ラテンアメリカ
11.3.1 市場動向
11.3.2 市場予測
11.4 アジア太平洋
11.4.1 市場動向
11.4.2 市場予測
11.5 中東・アフリカ
11.5.1 市場動向
11.5.2 市場予測
12 様々な適応症における医療用大麻の有用性を示唆する臨床研究の概要
12.1 アルツハイマー病
12.2 自閉症
12.3 癌
12.4 慢性疼痛
12.5 てんかん
12.6 偏頭痛
12.7 消化器疾患
12.8 多発性硬化症
12.9 統合失調症
12.10 その他
13 競争環境
13.1 市場構造
13.2 主要プレイヤー
14 主要プレーヤーのプロフィール
14.1 キャノピー・グロース・コーポレーション
14.2 GWファーマシューティカルズ plc
14.3 Aurora Cannabis, Inc.
14.4 アフリア・インク
14.5 メドリーフ・コーポレーション
14.6 インシス・セラピューティクス社
14.7 カニメッド・セラピューティクス社
14.8 カラ・セラピューティクス社
14.9 ユナイテッド・カンナビス・コーポレーション
図1：世界：医療用大麻市場：主な推進要因と課題
図2：世界：医療用大麻市場：金額推移（単位：10億米ドル）、2019年〜2024年
図3：世界：医療用大麻市場：品種別構成比（単位：%）、2024年
図4：世界：医療用大麻市場：誘導体別構成比（%）、2024年
図5：世界：医療用大麻市場：用途別構成比（%）、2024年
図6：世界：医療用大麻市場：医療用大麻の世界市場：用途別構成比（%）、2024年
図7：世界：医療用大麻市場：図7：医療用大麻の世界市場：投与経路別構成比（%）、2024年
図8：世界：医療用大麻市場：地域別構成比（%）、2024年
図9：医療用大麻の世界市場予測：金額推移（単位：億米ドル）、2025年～2033年
図10：世界：医療用大麻産業：SWOT分析
図11：世界：医療用大麻産業：バリューチェーン分析
図12：世界：医療用大麻産業：ポーターのファイブフォース分析
図13：世界：医療用大麻市場（インディカ）：金額推移（単位：百万米ドル）、2019年および2024年
図14：世界：医療用大麻市場予測（インディカ）：金額推移（単位：百万米ドル）、2025年～2033年
図15：世界：医療用大麻市場（サティバ）：金額推移（単位：百万米ドル）、2019年・2024年
図16：世界：医療用大麻市場予測（サティバ）：金額推移（単位：百万米ドル）、2025年～2033年
図17：世界：医療用大麻市場（ハイブリッド）：金額推移（単位：百万米ドル）、2019年・2024年
図18：世界の医療用大麻市場予測（ハイブリッド）：金額推移（単位：百万米ドル）、2025年～2033年
図19：世界の医療用大麻市場（カンナビジオール-CBD）：金額推移（単位：百万米ドル）、2019年・2024年
図20：世界：医療用大麻市場予測（カンナビジオール-CBD）：金額推移（単位：百万米ドル）、2025年～2033年
図21：世界：医療用カンナビス市場（テトラヒドロカンナビノール-THC）：金額推移（単位：百万米ドル）、2019年・2024年
図22：世界：医療用大麻市場予測（テトラヒドロカンナビノール-THC）：金額推移（単位：百万米ドル）、2025年～2033年
図23：世界：医療用大麻市場（その他の誘導体）：金額推移（単位：百万米ドル）、2019年・2024年
図24：世界：医療用大麻市場予測（その他の誘導体）：金額推移（単位：百万米ドル）、2025年～2033年
図25：世界：医療用大麻市場（癌への応用）：金額推移（単位：百万米ドル）、2019年・2024年
図26：医療用大麻の世界市場世界：医療用大麻市場の予測（癌における用途）：金額推移（単位：百万米ドル）、2025年～2033年
図27：医療用大麻の世界市場世界：医療用大麻市場（関節炎への応用）：金額推移（単位：百万米ドル）、2019年・2024年
図28：世界：医療用大麻市場の予測（関節炎における用途）：金額推移（単位：百万米ドル）、2025年～2033年
図29：世界：医療用大麻市場（片頭痛における用途）：金額推移（単位：百万米ドル）、2019年・2024年
図30：世界：医療用大麻市場の予測（片頭痛における用途）：金額推移（単位：百万米ドル）、2025年～2033年
図31：世界：医療用大麻市場（てんかんにおける用途）：金額推移（単位：百万米ドル）、2019年・2024年
図32：世界：医療用大麻市場の予測（てんかんにおける用途）：金額推移（単位：百万米ドル）、2025年～2033年
図33：世界：医療用大麻市場（その他の用途）：金額推移（単位：百万米ドル）、2019年・2024年
図34：世界：医療用大麻市場の予測（その他の用途）：金額推移（単位：百万米ドル）、2025年～2033年
図35：医療用大麻の世界市場世界：医療用大麻市場（製薬業界の最終用途）：金額推移（単位：百万米ドル）、2019年・2024年
図36：医療用大麻の世界市場世界：医療用大麻市場の予測（医薬品産業における最終用途）：金額推移（単位：百万米ドル）、2025年～2033年
図37：医療用大麻の世界市場世界：医療用大麻市場予測（研究開発センターにおける最終用途）：金額推移（単位：百万米ドル）、2019年・2024年
図38：世界：医療用大麻市場予測（研究開発センターにおける最終用途）：金額推移（単位：百万米ドル）、2025年～2033年
図39：医療用大麻の世界市場世界：医療用大麻市場（その他の最終用途）：金額推移（単位：百万米ドル）、2019年・2024年
図40：世界：医療用大麻市場の予測（その他の最終用途）：金額推移（単位：百万米ドル）、2025年～2033年
図41：世界：医療用大麻市場（内服液とカプセルによる投与）：金額推移（単位：百万米ドル）、2019年・2024年
図42：世界：医療用大麻市場予測（経口剤とカプセルによる投与）：金額推移（単位：百万米ドル）、2025年～2033年
図43：世界：医療用大麻市場（気化器による投与）の予測：2025-2033年金額推移（単位：百万米ドル）、2019年・2024年
図44：世界：医療用大麻市場の予測（気化器による投与）：金額推移（単位：百万米ドル）、2025年～2033年
図45：世界：医療用大麻市場（外用剤による投与）：金額推移（単位：百万米ドル）、2019年・2024年
図46：世界：医療用大麻市場の予測（外用薬による投与）：金額推移（単位：百万米ドル）、2025年～2033年
図47：世界：医療用大麻市場（その他の投与経路）：金額推移（単位：百万米ドル）、2019年・2024年
図48：世界：医療用大麻市場予測（その他の投与経路）：金額推移（単位：百万米ドル）、2025年～2033年
図49：北米：医療用大麻市場医療用大麻市場：金額推移（単位：百万米ドル）、2019年・2024年
図50：北米：医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図51：米国：医療用大麻市場医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図52：米国：医療用大麻市場の予測医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図53：カナダ医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図54：カナダ：医療用大麻市場の予測医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図55：ヨーロッパ：医療用大麻市場医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図56：欧州：医療用大麻市場の予測医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図57：ドイツ医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図58：ドイツ：医療用大麻市場の予測医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図59：イタリア：医療用大麻市場医療用大麻市場：金額推移（単位：百万米ドル）、2019年・2024年
図60：イタリア医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図61：フランス：医療用大麻市場医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図62：フランス：医療用大麻市場の予測医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図63：オランダ：医療用大麻市場医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図64：オランダ：医療用大麻市場予測医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図65：スペイン医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図66：スペインの医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図67：ラテンアメリカの医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図68：ラテンアメリカの医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図69：アジア太平洋地域医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図70：アジア太平洋地域医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
図71：中東とアフリカ：医療用大麻市場：金額推移（単位：百万米ドル）、2019年および2024年
図72：中東およびアフリカ：医療用大麻市場の予測：金額推移（単位：百万米ドル）、2025年～2033年
表一覧
表1：世界：医療用大麻市場：主要産業ハイライト、2024年および2033年
表2：世界：医療用大麻市場予測：種類別内訳（単位：百万米ドル）、2025年〜2033年
表3：世界：医療用大麻市場の予測：派生物別の内訳（単位：百万米ドル）、2025-2033年
表4：世界：医療用大麻市場の予測：用途別構成比（単位：百万米ドル）、2025-2033年
表5：世界：医療用大麻市場の予測：用途別構成比（単位：百万米ドル）、2025-2033年
表6：世界：医療用大麻市場の予測：投与経路別構成比（単位：百万米ドル）、2025-2033年
表7：世界の医療用大麻市場予測：地域別構成比（単位：百万米ドル）、2025-2033年
表8：世界の医療用大麻市場：競争構造
表9：世界：医療用大麻市場：主要プレイヤー
The global medical cannabis market size reached USD 37.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 68.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.1% during 2025-2033. The increasing product use in treating substance use disorders, the exploration of products for chronic inflammatory conditions, the rising product demand for gastrointestinal disorders, and the rising demand for CBD-based products are some of the factors propelling the market.
Medical cannabis, also known as medical marijuana, is a plant-based medicine derived from the Cannabis sativa or Cannabis indica species. It contains cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the body's endocannabinoid system to produce therapeutic effects. It has shown potential in alleviating symptoms and managing various medical conditions, including chronic pain, epilepsy, multiple sclerosis, and nausea caused by chemotherapy. Its medicinal use has been legalized in many countries and states, subject to strict regulations and medical prescriptions. Research on medical cannabis continues to grow, exploring its efficacy in treating various health conditions.
The global market is majorly driven by the increasing acceptance of the product for medicinal purposes. In line with this, the expanding legalization of the product is significantly contributing to the market. Furthermore, the rising awareness of the potential therapeutic benefits of the product is positively influencing the market. Apart from this, the rapid advancements in cannabis research and medical studies are offering numerous opportunities for the market. Moreover, the growing prevalence of chronic pain and other medical conditions treatable with the product is catalyzing the market. Besides, the escalating aging population seeking alternative treatments for age-related ailments is propelling the market. The opioid crisis and the search for safer pain management options are bolstering the market. Additionally, the increasing demand for natural and plant-based medicines is providing a boost to the market.
Medical Cannabis Market Trends/Drivers:
Rising clinical trials, research and development (R&D) activities, and commercialization of cannabis-based indications
The rising clinical trials, research and development (R&D) activities, and commercialization of cannabis-based indications are fostering the market. With increasing acceptance and legalization, there is a growing interest among researchers, pharmaceutical companies, and medical professionals to explore the potential therapeutic benefits of the product. Clinical trials and research studies are essential to provide scientific evidence supporting the efficacy and safety of cannabis-based treatments for various medical conditions. As more positive results emerge from these studies, confidence in medical cannabis as a legitimate treatment options increases, leading to wider adoption. Furthermore, commercializing cannabis-based indications has seen substantial investments from pharmaceutical companies and startups. The development of standardized cannabis-based pharmaceutical products offers more consistent dosing, quality control, and regulatory compliance, further legitimizing the product in the healthcare industry. As the product becomes more firmly integrated into mainstream medicine, the market is expected to expand, attracting more patients, healthcare providers, and investors. This positive momentum in research, development, and commercialization fuels the market.
Inflating disposable incomes of the consumers
The inflating disposable incomes of the consumers are favorably impacting the market. As disposable incomes rise, consumers have more financial capacity to spend on healthcare, including alternative and complementary treatments. With increased purchasing power, individuals are more likely to explore and invest in the product for various health conditions. Medical cannabis, which may not be covered by insurance in some regions, can become a viable option for consumers with higher disposable incomes. Inflating disposable incomes also contribute to a shift in consumer preferences towards more holistic and natural health remedies. As individuals prioritize their well-being, they seek alternative treatments beyond traditional pharmaceuticals, leading to increased demand for the product. Additionally, higher disposable incomes allow consumers to afford these products that may be of higher quality or from reputable sources, boosting the premium segment of the market.
The emergence of new cannabis-based pharmaceutical products
The emergence of new cannabis-based pharmaceutical products is bolstering the market. As research and clinical trials continue to explore the therapeutic potential of cannabinoids and other cannabis-derived compounds, pharmaceutical companies are developing innovative cannabis-based medications. These new pharmaceutical products undergo rigorous testing and regulatory approvals, instilling confidence in medical professionals and patients about their safety and efficacy. As a result, more healthcare providers are open to prescribing cannabis-based medications for various medical conditions, thus driving market adoption. The development of standardized cannabis-based pharmaceuticals also addresses concerns about dosage consistency and quality control, making them more reliable and appealing to patients and healthcare providers. Moreover, the emergence of new cannabis-based medications expands the potential applications of medical cannabis in treating a wide range of conditions, from chronic pain and neurological disorders to mental health ailments.
Medical Cannabis Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global medical cannabis market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on species, derivatives, application, end-use and route of administration.
Breakup by Species:
Indica
Sativa
Hybrid
Indica dominates the market
The report has provided a detailed breakup and analysis of the market based on the species. This includes indica, sativa, and hybrid. According to the report, indica represented the largest segment.
As one of the primary cannabis species, Cannabis indica is known for its high CBD content and relatively lower THC levels compared to Cannabis sativa. The increased interest in CBD-based products and therapeutic applications has boosted the demand for Cannabis indica strains. CBD is recognized for its potential benefits in managing various health conditions, such as pain, anxiety, and inflammation, without inducing the psychoactive effects commonly associated with THC.
Moreover, Indica's relaxing and sedative properties make it appealing for medicinal use in addressing sleep disorders and promoting relaxation. As consumers seek natural alternatives to traditional medications, Cannabis indica is increasingly sought after as a potential treatment option. The evolving legal landscape and greater acceptance of medical cannabis have also contributed to the market growth of Cannabis indica products. With the increasing number of states and countries legalizing medical cannabis, indica strains are gaining traction among patients and healthcare professionals, propelling market expansion further.
Breakup by Derivatives:
Cannabidiol (CBD)
Tetrahydrocannabinol (THC)
Others
Tetrahydrocannabinol (THC) dominates the market
The report has provided a detailed breakup and analysis of the market based on the derivatives. This includes cannabidiol (CBD), tetrahydrocannabinol (THC), and others. According to the report, THC represented the largest segment.
Tetrahydrocannabinol (THC) is crucial in propelling the market due to its psychoactive properties and potential therapeutic benefits. As one of the primary cannabinoids found in cannabis, THC is known for its ability to interact with the body's endocannabinoid system, producing various physiological and psychological effects. The psychoactive nature of THC attracts a segment of consumers seeking relief from pain, stress, and anxiety, making it an appealing option for medicinal use. Patients with chronic pain, cancer-related symptoms, and multiple sclerosis may find THC-containing medical cannabis products beneficial in managing their symptoms.
Furthermore, the recreational use of THC has helped destigmatize cannabis overall, leading to increased acceptance and legalization of medical cannabis in various regions. This evolving legal landscape has contributed to the market growth of medical cannabis, making it more accessible to patients in need. As research continues to explore the potential medical applications of THC and its combination with other cannabinoids, the demand for products containing THC is expected to grow, further driving the market expansion.
Breakup by Application:
Cancer
Arthritis
Migraine
Epilepsy
Others
Cancer dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer, arthritis, migraine, epilepsy, and others. According to the report, cancer represented the largest segment.
Cancer is a significant market driver due to its potential to manage cancer-related symptoms and side effects of cancer treatments. Medical cannabis has shown promise in alleviating chemotherapy-induced nausea and vomiting and stimulating appetite in cancer patients experiencing cachexia and weight loss. Moreover, cancer-related pain management is critical for medical cannabis usage, as cannabinoids, including THC and CBD, may offer analgesic properties. Patients seeking alternatives to traditional pain medications are turning to medical cannabis to manage pain and improve their quality of life.
Furthermore, medical cannabis may have anti-inflammatory and anti-tumor properties, sparking interest in its potential role as an adjunct therapy in cancer treatment. Research continues to explore these possibilities, driving the demand for medical cannabis products. The growing number of cancer patients and increasing acceptance of medical cannabis as a complementary treatment option contributes to market growth. As medical professionals recognize the potential benefits, cancer patients are increasingly incorporating medical cannabis into their treatment plans, further fueling the market.
Breakup by End-Use:
Pharmaceutical Industry
Research and Development Centres
Others
Pharmaceutical industry dominates the market
The report has provided a detailed breakup and analysis of the market based on the end-use. This includes the pharmaceutical industry, research and development centres, and others. According to the report, the pharmaceutical industry represented the largest segment.
The pharmaceutical industry is pivotal in strengthening the market through extensive research and development, and commercialization of cannabis-based medications. As the potential therapeutic benefits of cannabinoids and cannabis-derived compounds gain recognition, pharmaceutical companies are investing in clinical trials and R&D activities to develop novel cannabis-based pharmaceutical products. These companies are exploring various delivery methods, formulations, and dosages to create standardized and regulated medical cannabis treatments. By developing pharmaceutical-grade cannabis products, they aim to address concerns about consistency, safety, and efficacy, which are essential for medical professionals and patients.
Furthermore, pharmaceutical companies' involvement in the medical cannabis market brings credibility and legitimacy to the industry, encouraging wider acceptance and adoption by healthcare professionals. This collaboration between the pharmaceutical industry and medical cannabis fosters the integration of cannabis-based treatments into mainstream medicine, driving market growth and expanding the scope of medical cannabis usage for various health conditions.
Breakup by Route of Administration:
Oral Solutions and Capsules
Vaporizers
Topicals
Others
Oral solutions and capsules dominate the market
The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral solutions and capsules, vaporizers, topicals and others. According to the report, oral solutions and capsules represented the largest segment.
Oral solutions and capsules are propelling the market due to their convenience, dosage accuracy, and ease of administration. As pharmaceutical companies develop standardized cannabis-based medications in these forms, patients can consume medical cannabis more discreetly and precisely. Oral solutions and capsules offer consistent dosing, making it easier for healthcare professionals to prescribe and monitor patient treatment. This standardization fosters confidence in medical cannabis as a legitimate therapeutic option.
Moreover, these delivery methods cater to patients who prefer a smoke-free and non-inhalation approach to medical cannabis consumption. They especially appeal to older adults and individuals seeking alternative treatments for various health conditions. The convenience of oral solutions and capsules contributes to better patient compliance, leading to more successful treatment outcomes. As medical cannabis gains wider acceptance and pharmaceutical-grade products become available in these forms, the market growth of medical cannabis is accelerated, attracting patients and healthcare professionals to explore its therapeutic potential further.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
Europe
Germany
France
Italy
Spain
Netherlands
Latin America
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest medical cannabis market share
The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific, Europe (Germany, Italy, France, the Netherlands, and Spain), Latin America, and Middle East and Africa. According to the report, North America accounted for the largest market share.
North America is fostering the market growth due to its progressive regulatory environment, increasing acceptance, and widespread legalization across various states and countries in the region. In particular, the United States and Canada have been at the forefront of the medical cannabis movement, with many states and provinces legalizing medical cannabis for therapeutic use. The growing awareness and acceptance of medical cannabis have increased patient demand as individuals seek alternative treatments for various medical conditions. This increasing demand, in turn, has spurred investments in research, development, and commercialization of medical cannabis products, driving market growth.
Moreover, well-established pharmaceutical companies and research institutions in North America have accelerated the development of standardized and regulated cannabis-based medications, further propelling market expansion. The evolving legal landscape, coupled with a strong consumer base and supportive healthcare policies, positions North America as a significant driving force behind the market's global growth.
Competitive Landscape:
Top companies are strengthening the market by leveraging their resources, expertise, and brand recognition. These companies invest heavily in research and development to create innovative cannabis-based products with consistent quality and efficacy. They expand their presence in key markets through strategic partnerships and acquisitions, driving consumer awareness and accessibility. Their established distribution networks enable the widespread availability of medical cannabis products, reaching a broader patient base. Furthermore, these companies also engage in educational initiatives to raise awareness among healthcare professionals and the general public about the therapeutic potential of medical cannabis. Their efforts to comply with regulatory standards and maintain product safety build trust and credibility in the industry. By setting high industry standards and fostering best practices, these companies contribute to the market growth, leading the way for continued expansion and acceptance of medical cannabis as a legitimate and effective treatment option.
The report has provided a comprehensive analysis of the competitive landscape in the medical cannabis market. Detailed profiles of all major companies have also been provided.
Canopy Growth Corporation
GW Pharmaceuticals, plc
Aurora Cannabis, Inc.
Aphria, Inc.
MedReleaf Corporation
Insys Therapeutics, Inc.
CanniMed Therapeutics, Inc.
Cara Therapeutics, Inc.
United Cannabis Corporation
Key Questions Answered in This Report
1. What was the size of the global medical cannabis market in 2024?
2. What is the expected growth rate of the global medical cannabis market during 2025-2033?
3. What are the key factors driving the global medical cannabis market?
4. What has been the impact of COVID-19 on the global medical cannabis market?
5. What is the breakup of the global medical cannabis market based on the species?
6. What is the breakup of the global medical cannabis market based on the derivatives?
7. What is the breakup of the global medical cannabis market based on the application?
8. What is the breakup of the global medical cannabis market based on end-use?
9. What is the breakup of the global medical cannabis market based on the route of administration?
10. What are the key regions in the global medical cannabis market?
11. Who are the key players/companies in the global medical cannabis market?
7. What is the breakup of the global medical cannabis market based on the application?
8. What is the breakup of the global medical cannabis market based on end-use?
9. What is the breakup of the global medical cannabis market based on the route of administration?
10. What are the key regions in the global medical cannabis market?
11. Who are the key players/companies in the global medical cannabis market?
